CROSS-REFERENCE TERMINAL ... SEE ALSO
  RECORD ................. /gsk-financial-impact-adolescent-paroxetine-2001-2015
  STATUS ................. COLD
  CROSS-REFERENCES ....... 4 (4 OUT / 0 IN)
  NAVIGATION ............. CLICK A CARD TO WALK THE ARCHIVE

GlaxoSmithKline Financial Impact from Adolescent Paroxetine Prescriptions (2001-2015)

◂ RECORDS ROOM PULL THE FULL ANNOTATION →

REGISTER

→ SHARES-EVENT Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias [file] — This dossier directly discusses the financial consequences stemming from the suppressed data and misleading publication of Study 329.
→ SUPPORTS Paroxetine Prescriptions for Adolescents (2001-2015) After Study 329 Publication [file] — This dossier provides context for the financial impact of the prescriptions discussed in the other document, particularly the sales figures and fines.
→ SHARES-EVENT Study 329 Adverse Event Data Exclusion and FDA Disclosure [file] — The misleading nature of Study 329's findings, which involved data exclusion, directly led to the illegal promotion and subsequent financial penalties for GSK.
→ SHARES-ACTOR GSK Contractual Restrictions on Paroxetine Research Publication [file] — This dossier concerns financial outcomes related to GSK's conduct regarding paroxetine publication, which is a shared actor and event.